Boehringer Ingelheim and Zealand Pharma have kicked ... consultant in metabolic medicine at University College in Dublin in Ireland, who was the principal investigator of the phase 2 trial.

The U.S. Food and Drug Administration (FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (aSyn-SAA) biomarker, discovered in 2023, for research and ...

Boehringer/Zealand injectable Meanwhile, data on another potential rival in the injectable obesity category from Boehringer Ingelheim and ... facility in Ireland that will be used to produce ...

The European Court of Justice ruled against Apple in a tax case regarding benefits received in Ireland, potentially leading ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...

INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic ...